The endothelium in diabetes: Its role in insulin access and diabetic complications

Reviews in Endocrine and Metabolic Disorders

Volumn 14, Issue 1, 2013, Pages 13-19

  Kolka, Cathryn M ^a   Bergman, Richard N ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Diabetes; Endothelium; Insulin; Interstitium; Muscle; Vascular

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; INSULIN; LOSARTAN; NITRIC OXIDE; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE;

ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; GLUCOSE METABOLISM; HORMONE ACTION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; METABOLIC SYNDROME X; MUSCLE CELL; OBESITY; PERIPHERAL NEUROPATHY; REVIEW; SKELETAL MUSCLE; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; MODELS, BIOLOGICAL;

EID: 84874646329     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-012-9233-5     Document Type: Review

References (63)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
2. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am. 2004;33(2):417-29. (Pubitemid 38684163)
3. Utsunomiya K. Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance. Vasc Health Risk Manag. 2012;8:429-36.
4. Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract. 2011;93 Suppl 1:S52-9.
5. Tack CJJ, Schefman AEP, Willems JL, Thien T, Lutterman JA, Smits P. Direct vasodilator effects of physiological hyperinsulin-aemia in human skeletal muscle. Eur J Clin Investig. 1996;26(9):772-8. (Pubitemid 26308649)
6. Eringa EC, Stehouwer CD, Merlijn T, Westerhof N, Sipkema P. Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res. 2002;56(3):464-71. (Pubitemid 35351568)
7. Verma S, Yao L, Stewart DJ, Dumont AS, Anderson TJ, McNeill JH. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo. Hypertension. 2001;37(2):328-33. (Pubitemid 32199095)
8. Rattigan S, Zhang L, Mahajan H, Kolka CM, Richards SM, Clark MG. Factors influencing the hemodynamic and metabolic effects of insulin in muscle. Curr Diabetes Rev. 2006;2(1):61-70. (Pubitemid 44082951)
9. Ellmerer M, Kim SP, Hamilton-Wessler M, Hucking K, Kirkman E, Bergman RN. Physiological hyperinsulinemia in dogs augments access of macromolecules to insulin-sensitive tissues. Diabetes. 2004;53(11):2741-7. (Pubitemid 39425898)
10. Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab. 2011;301(2):E252-63.
11. Serne EH, Ijzerman RG, Gans RO, Nijveldt R, de Vries G, Evertz R, Donker AJ, Stehouwer CD. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes. 2002;51(5):1515-22. (Pubitemid 34826619)
12. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barrett EJ. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes. 2004;53(6):1418-23. (Pubitemid 38697651)
13. Chiu JD, Richey JM, Harrison LN, Zuniga E, Kolka CM, Kirkman EL, Ellmerer M, Bergman RN. Direct administration of insulin into skeletal muscle reveals that the transport of insulin across the capillary endothelium limits the time course of insulin to activate glucose disposal. Diabetes. 2008;57(4):828-35.
14. Barrett EJ, Rattigan S. Muscle perfusion: its measurement and role in metabolic regulation. Diabetes. 2012;61(11):2661-8.
15. Steil GM, Ader M, Moore DM, Rebrin K, Bergman RN. Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process. J Clin Investig. 1996;97(6):1497-503.
16. Brunner F, Wascher TC. Contribution of the endothelium to transcapillary insulin transport in rat isolated perfused hearts. Diabetes. 1998;47(7):1127-34. (Pubitemid 28294557)
17. Majumdar S, Genders AJ, Inyard AC, Frison V, Barrett EJ. Insulin entry into muscle involves a saturable process in the vascular endothelium. Diabetologia. 2012;55(2):450-6.
18. Wang H, Liu Z, Li G, Barrett EJ. The vascular endothelial cell mediates insulin transport into skeletal muscle. Am J Physiol Endocrinol Metab. 2006;291(2):E323-32. (Pubitemid 44035292)
19. Wang H, Wang AX, Barrett EJ. Caveolin-1 is required for vascular endothelial insulin uptake. Am J Physiol Endocrinol Metab. 2011;300(1):E134-44.
20. Ader M, Bergman RN. Importance of transcapillary insulin transport to dynamics of insulin action after intravenous glucose. Am J Physiol. 1994;266(1 Pt 1):E17-25.
21. Sjostrand M, Holmang A, Lonnroth P. Measurement of interstitial insulin in human muscle. Am J Physiol. 1999;276(1 Pt 1):E151-4.
22. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, Itoh S, Takamoto I, Sasako T, Kumagai K, Kawai T, Hashimoto S, Kobayashi T, Sato M, Tokuyama K, Nishimura S, Tsunoda M, Ide T, Murakami K, Yamazaki T, Ezaki O, Kawamura K, Masuda H, Moroi M, Sugi K, Oike Y, Shimokawa H, Yanagihara N, Tsutsui M, Terauchi Y, Tobe K, Nagai R, Kamata K, Inoue K, Kodama T, Ueki K, Kadowaki T. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab. 2011;13(3):294-307.
23. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Investig. 2003;111(9):1373-80. (Pubitemid 36554708)
24. Chiu JD, Kolka CM, Richey JM, Harrison LN, Zuniga E, Kirkman EL, Bergman RN. Experimental hyperlipidemia dramatically reduces access of insulin to canine skeletal muscle. Obesity (SilverSpring).2009;17(8):1486-92.
25. Kolka CM, Harrison LN, Lottati M, Chiu JD, Kirkman EL, Bergman RN. Diet-induced obesity prevents interstitial dispersion of insulin in skeletal muscle. Diabetes. 2009;59(3):619-26.
26. Sandqvist M, Strindberg L, Schmelz M, Lonnroth P, Jansson PA. Impaired delivery of insulin to adipose tissue and skeletal muscle in obese women with postprandial hyperglycemia. J Clin Endocrinol Metab. 2011;96(8):E1320-4.
27. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, Tabit CE, Hamburg NM, Frame AA, Caiano TL, Kluge MA, Duess MA, Levit A, Kim B, Hartman ML, Joseph L, Shirihai OS, Vita JA. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation. 2011;124(4):444-53.
28. Sharma A, Bernatchez PN, de Haan JB. Targeting endothelial dysfunction in vascular complications associated with diabetes. Int J Vasc Med. 2012. doi: 10.1155/2012/750126.
29. Goldfine AB, Beckman JA, Betensky RA, Devlin H, Hurley S, Varo N, Schonbeck U, Patti M E, Creager MA (2006) Family history of diabetes is a major determinant of endothelial function. J.Am.Coll.Cardiol., %20;47(12), 2456-2461. (Pubitemid 43866372)
30. Farb MG, Ganley-Leal L, Mott M, Liang Y, Ercan B, Widlansky ME, Bigornia SJ, Fiscale AJ, Apovian CM, Carmine B, Hess DT, Vita JA, Gokce N. Arteriolar function in visceral adipose tissue is impaired in human obesity. Arterioscler Thromb Vasc Biol. 2011;32(2):467-73.
31. Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J Clin Endocrinol Metab. 2011;96(2):438-46.
32. El Akoum S, Cloutier I, Tanguay JF. Vascular smooth muscle cell alterations triggered by mice adipocytes: role of high-fat diet. J Atheroscler Thromb. 2012;19(12):1128-41.
33. Yudkin JS, Eringa E, Stehouwer CD. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365(9473):1817-20. (Pubitemid 40744663)
34. Iwata NG, Pham M, Rizzo NO, Cheng AM, Maloney E, Kim F. Trans fatty acids induce vascular inflammation and reduce vascular nitric oxide production in endothelial cells. PLoS One. 2011;6(12):e29600.
35. Rask-Madsen C, Li Q, Freund B, Feather D, Abramov R, Wu IH, Chen K, Yamamoto-Hiraoka J, Goldenbogen J, Sotiropoulos KB, Clermont A, Geraldes P, Dall'Osso C, Wagers AJ, Huang PL, Rekhter M, Scalia R, Kahn CR, King GL. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab. 2010;11(5):379-89.
36. Satchell SC. The glomerular endothelium emerges as a key player in diabetic nephropathy. Kidney Int. 2012;82(9):949-51.
37. Tremolada G, Del Turco C, Lattanzio R, Maestroni S, Maestroni A, Bandello F, Zerbini G. The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. Exp Diabetes Res. 2012. doi: 10.1155/2012/728325.
38. Exalto LG, Whitmer RA, Kappele LJ, Biessels GJ. An update on type 2 diabetes, vascular dementia and Alzheimer's disease. Exp Gerontol. 2012;47(11):858-64.
39. Kolka CM, Bergman RN. The barrier within: endothelial transport of hormones. Physiology (Bethesda). 2012;27(4):237-47.
40. Florey. The endothelial cell. Br Med J. 1966;2(5512):487-90.
41. Villela NR, Kramer-Aguiar LG, Bottino DA, Wiernsperger N, Bouskela E. Metabolic disturbances linked to obesity: the role of impaired tissue perfusion. Arq Bras Endocrinol Metabol. 2009;53(2):238-45.
42. Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serne EH, Smulders YM, Stehouwer CD. Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals. Microvasc Res. 2011;82(1):77-83.
43. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int J Biochem Cell Biol. 2006;38(5-6):766-81. (Pubitemid 43372054)
44. Muniyappa R, Yavuz S. Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act. Mol Cell Endocrinol. 2012. doi: 10.1016/j.mce.2012.05.017.
45. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway. Pharmacol Res. 2012;66(1):41-50.
46. Chai W, Wang W, Dong Z, Cao W, Liu Z. Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo. Diabetes. 2011;60(11):2939-46.
47. Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T, Mancia G, Volpe M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens. 2011;24(5):582-90.
48. van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care. 2011;34(4):845-51.
49. Murrow JR, Sher S, Ali S, Uphoff I, Patel R, Porkert M, Le NA, Jones D, Quyyumi AA. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol. 2012;6(1):42-9.
50. Tian XY, Wong WT, Xu A, Chen ZY, Lu Y, Liu LM, Lee VW, Lau CW, Yao X, Huang Y. Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. Br J Pharmacol. 2011;164(2b):598-606.
51. Sgarra L, Addabbo F, Potenza MA, Montagnani M. Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology. Am J Physiol Endocrinol Metab. 2012;302(10):E1171- 82.
52. Gealekman O, Guseva N, Gurav K, Gusev A, Hartigan C, Thompson M, Malkani S, Corvera S. Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial. Diabetologia. 2012;55(10):2794-9.
53. Omae T, Nagaoka T, Tanano I, Yoshida A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, induces dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels. Invest Ophthalmol Vis Sci. 2011;52(9):6749-56.
54. Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010;325(1-2):26-35.
55. Chai W, Dong Z, Wang W, Tao L, Cao W, Liu Z. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. 2012;61(4):888-96.
56. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54(4):965-78.
57. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, Matsumoto M, Mizutani K, Park K, Cahill C, Nishikawa SI, Rask-Madsen C, King GL. Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCbeta Activation in Diabetes. Diabetes. 2012;61(11):2967-79.
58. Forst T, Weber MM, Pfutzner A. Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res. 2012. doi: 10.1155/2012/635472.
59. Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J. 2011;35(5):437-43.
60. Georgescu A. Vascular dysfunction in diabetes: The endothelial progenitor cells as new therapeutic strategy. World J Diabetes. 2011;2(6):92-7.
61. Kim JY, Song SH, Kim KL, Ko JJ, Im JE, Yie SW, Ahn YK, Kim DK, Suh W. Human cord blood-derived endothelial progenitor cells and their conditioned media exhibit therapeutic equivalence for diabetic wound healing. Cell Transplant. 2010;19(12):1635-44.
62. Fan Y, Shen F, Frenzel T, Zhu W, Ye J, Liu J, Chen Y, Su H, Young WL, Yang GY. Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol. 2010;67(4):488-97.
63. Jujo K, Hamada H, Iwakura A, Thorne T, Sekiguchi H, Clarke T, Ito A, Misener S, Tanaka T, Klyachko E, Kobayashi K, Tongers J, Roncalli J, Tsurumi Y, Hagiwara N, Losordo DW. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci U S A. 2010;107(24):11008-13.